When will Pralsetinib be available?

While the Phase 1/2 trial of Pralsetinib, namedARROW, is still ongoing, Pralsetinib received accelerated approval from the U.S. Food and Drug Administration (FDA) on September 4, 2020, for the treatment of metastatic RET-positive non-small cell lung cancer. It is currently sold under the tradename GAVRETO by Blueprint Medicines.

In November 2021, the European Medicines Agency (EMA) concluded that the benefits of platinib outweigh the risks. A major study showed that platinib effectively shrank tumors in patients with RET fusion-positive non-small cell lung cancer, and the side effects currently observed are considered controllable. In March 2021, Platinib was approved by the National Medical Products Administration and was launched in China with the trade name Pujihua. Platinib is the first highly selective rearrangement during transfection (RET) inhibitor currently approved in Hong Kong, China, for the treatment of RET fusion-positive metastatic non-small cell lung cancer.

The original drug Platinib marketed in China has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.